Research
Hormonal
NAMPT (Nicotinamide Phosphoribosyltransferase) is the rate-limiting enzyme in the NAD+ salvage pathway and serves as a critical link between circadian rhythms and metabolism.
Your body's ability to produce NAD+ is regulated by a key enzyme called NAMPT, which follows a daily (circadian) rhythm. Eating at consistent times and maintaining a regular sleep-wake cycle may support this enzyme's function, thereby supporting your metabolic health.
ModerateSupportsMEDIUM confidence
NAMPT, which is the rate-limiting step of this part of the pathway... is considered an important regulatory enzyme with respect to the NAD+ consumers, notably the aging-associated histone deacetylase SIRT1.
Why this rating
Based on cited studies regarding NAMPT expression and regulation.
Source
The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways
Riekelt H. Houtkooper et al. · Endocrine Reviews · 2010
DOI 10.1210/er.2009-0026
narrative_reviewCited 880×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Modulation of NAD+ metabolism, specifically through the salvage pathway enzyme NAMPT and its product NMN, acts as a metabolic sensor that regulates energy metabolism, oxidative metabolism, and potentially extends lifespan.Moderate
- Sirtuins are NAD+-dependent protein deacetylases that function as metabolic sensors, linking cellular NAD+ levels to downstream metabolic pathways and gene expression.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →